Analytical Data
-
基因名
TNFSF10
- Application
-
别名
TNFSF10；APO2L；Tumor necrosis factor ligand superfamily member 10
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P50591
-
表达区间
39-281aa
-
氨基酸序列
TNELKQMQDKYSKSGIACFLKEDDSYWDPNDEESMNSPCWQVKWQLRQLVRKMILRTSEETISTVQEKQQNISPLVRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG
-
分子量
32.4kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TNFSF10, also known as TRAIL (TNF-related apoptosis-inducing ligand), is a member of the tumor necrosis factor superfamily that plays a crucial role in regulating apoptosis, particularly in cancer cells. This protein can bind to specific receptors on the surface of target cells, triggering apoptotic pathways that lead to cell death, making it a significant focus of cancer research. Due to its selective cytotoxicity towards tumor cells while sparing normal cells, TNFSF10 has garnered attention as a promising therapeutic agent for cancer treatment. Research has focused on the recombinant production of TNFSF10 to enhance its stability, bioactivity, and therapeutic potential. Advances in recombinant DNA technology and expression systems enable the large-scale production of TNFSF10 for preclinical and clinical studies, allowing researchers to explore its efficacy when used alone or in combination with other therapies. Furthermore, understanding its mechanisms of action and resistance factors constitutes a vital area of investigation aimed at optimizing its clinical application. The ongoing studies also emphasize developing strategies to overcome potential resistance in cancer cells, thereby enhancing the effectiveness of TNFSF10-based therapies. Overall, the study of TNFSF10 as a recombinant protein represents a promising avenue in the quest for novel and effective anti-cancer treatments, highlighting its potential in precision medicine approaches.
